Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4006 Comments
1159 Likes
1
Saniylah
Consistent User
2 hours ago
{协议答案}
👍 54
Reply
2
Raymondo
Elite Member
5 hours ago
{协议答案}
👍 25
Reply
3
Tyrisha
Insight Reader
1 day ago
{协议答案}
👍 250
Reply
4
Shpresa
Active Reader
1 day ago
{协议答案}
👍 185
Reply
5
Caroljo
Consistent User
2 days ago
{协议答案}
👍 123
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.